Medical Research News

Cannabinoid Receptor 2 Functional Variant Contributes to the Risk for Pediatric Inflammatory Bowel Disease

Written by Cara Wietstock

This is an example of audio post format. It supports all embedded audio URLs as well as self-hosted audio files.

A study conducted by Strisciuglio C1, Bellini G, Miele E, Martinelli M, Cenni S, Tortora C, Tolone C, Miraglia Del Giudice E, Rossi F. in November 2016 looked into the connection between Cannabinoid Receptor 2 and Pediatric Inflammatory Bowel Disease. The goal of the study was to establish the role of the cannabinoid receptor 2 functional variant Q63R in susceptibility to IBD.
The doctors genotyped 217 various pediatric IBD patients with diseases ranging from Chron’s disease to Colitis with a theory that endocannabinoids would limit intestinal inflammation through cannabinoid receptor 1 or 2. The results were significant and showed that CB2-W63R does contribute to the risk for pediatric IBD, specifically CD.

About the author

Cara Wietstock

Cara began working in the retail cannabis industry of San Francisco, CA in 2011 and continued in that sector for years. In 2015 she dedicated herself to writing full-time. Her passion for the written word and deep respect for the healing properties of the plant have brought her to Terpenes and Testing magazine. She now helps keep us on the cutting edge of scientific cannabis discovery as the Editor-in-Chief of the print publication.

Leave a Comment